Colm J O'Rourke1, Matthias S Matter2, Chirag Nepal1, Rui Caetano-Oliveira3,4, Phuongnga T Ton5, Valentina M Factor6, Jesper B Andersen1. 1. Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 2. Institute of Pathology, University Hospital of Basel, Basel, Switzerland. 3. Pathology Department, University Hospital (CHUC), Coimbra, Portugal. 4. Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal. 5. Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD. 6. Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD.
Abstract
Cholangiocarcinoma (CCA) mortality rates are increasing as a result of rising incidence and limited curative treatment(s) for patients with advanced disease. NOTCH pathway reactivation has been reported in biliary malignancies to conflicting degrees, hindering prioritization of key therapeutic targets within the network and identification of candidate responder patients for NOTCH-directed therapies. We analyzed genomic data from 341 patients with CCA and identified NOTCH1 significantly increased in a subgroup characterized by distinct stromal infiltration. Network-wide imbalance of the NOTCH pathway was seen in CCA, including correlation of NOTCH1 with NOTCH3 and NOTCH ligands. Given the diversity of observed NOTCH receptor engagement, γ-secretase modulation was rationalized as a therapeutic option. Indeed, subcutaneous transplantation of sensitive and resistant CCA cell lines pretreated with a γ-secretase inhibitor (GSi) cocktail demonstrated the antineoplastic effects of GSi in a subset of CCA and led to the development of a 225-gene responder signature. This signature was validated in an independent cohort of 119 patients. Further, this signature was enriched in liver tumors initiated by hydrodynamic injections of activated-NOTCH as compared with the AKT-RAS-driven tumors. Candidate GSi-responder patients were characterized by distinct transcriptomes overlapping with previous hepatobiliary metastasis and stemness, unique stromal properties, and dysfunctional intratumoral immune infiltration. Pan-cancer analysis identified 41.9% of cancer types to harbor prospective GSi-responder patients, which was adapted into a 20-gene GSi-sensitivity score metric capable of discriminating nanomolar versus micromolar sensitivity to a cell-permeable GSi (Z-LLNle-CHO) across 60 diverse tumor lines (area under the curve = 1). Conclusion: We have established a GSi-responder signature with evidence across several patient cohorts, as well as in vitro and in vivo models, to enable precision medicine application of NOTCH-directed therapy in CCA as well as prospectively across diverse malignancies.
Cholangiocarcinoma (CCA) mortality rates are increasing as a result of rising incidence and limited curative treatment(s) for patients with advanced disease. NOTCH pathway reactivation has been reported in biliary malignancies to conflicting degrees, hindering prioritization of key therapeutic targets within the network and identification of candidate responder patients for NOTCH-directed therapies. We analyzed genomic data from 341 patients with CCA and identified NOTCH1 significantly increased in a subgroup characterized by distinct stromal infiltration. Network-wide imbalance of the NOTCH pathway was seen in CCA, including correlation of NOTCH1 with NOTCH3 and NOTCH ligands. Given the diversity of observed NOTCH receptor engagement, γ-secretase modulation was rationalized as a therapeutic option. Indeed, subcutaneous transplantation of sensitive and resistant CCA cell lines pretreated with a γ-secretase inhibitor (GSi) cocktail demonstrated the antineoplastic effects of GSi in a subset of CCA and led to the development of a 225-gene responder signature. This signature was validated in an independent cohort of 119 patients. Further, this signature was enriched in liver tumors initiated by hydrodynamic injections of activated-NOTCH as compared with the AKT-RAS-driven tumors. Candidate GSi-responder patients were characterized by distinct transcriptomes overlapping with previous hepatobiliary metastasis and stemness, unique stromal properties, and dysfunctional intratumoral immune infiltration. Pan-cancer analysis identified 41.9% of cancer types to harbor prospective GSi-responder patients, which was adapted into a 20-gene GSi-sensitivity score metric capable of discriminating nanomolar versus micromolar sensitivity to a cell-permeable GSi (Z-LLNle-CHO) across 60 diverse tumor lines (area under the curve = 1). Conclusion: We have established a GSi-responder signature with evidence across several patient cohorts, as well as in vitro and in vivo models, to enable precision medicine application of NOTCH-directed therapy in CCA as well as prospectively across diverse malignancies.
Authors: Milind Javle; Maeve Lowery; Rachna T Shroff; Karl Heinz Weiss; Christoph Springfeld; Mitesh J Borad; Ramesh K Ramanathan; Lipika Goyal; Saeed Sadeghi; Teresa Macarulla; Anthony El-Khoueiry; Robin Kate Kelley; Ivan Borbath; Su Pin Choo; Do-Youn Oh; Philip A Philip; Li-Tzong Chen; Thanyanan Reungwetwattana; Eric Van Cutsem; Kun-Huei Yeh; Kristen Ciombor; Richard S Finn; Anuradha Patel; Suman Sen; Dale Porter; Randi Isaacs; Andrew X Zhu; Ghassan K Abou-Alfa; Tanios Bekaii-Saab Journal: J Clin Oncol Date: 2017-11-28 Impact factor: 44.544
Authors: Itaru Endo; Mithat Gonen; Adam C Yopp; Kimberly M Dalal; Qin Zhou; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Yuman Fong; Lawrence Schwartz; Nancy Kemeny; Eileen O'Reilly; Ghassan K Abou-Alfa; Hiroshi Shimada; Leslie H Blumgart; William R Jarnagin Journal: Ann Surg Date: 2008-07 Impact factor: 12.969
Authors: Anthony W Tolcher; Wells A Messersmith; Stanislaw M Mikulski; Kyriakos P Papadopoulos; Eunice L Kwak; Darlene G Gibbon; Amita Patnaik; Gerald S Falchook; Arvind Dasari; Geoffrey I Shapiro; John F Boylan; Zhi-Xin Xu; Ka Wang; Astrid Koehler; James Song; Steven A Middleton; Jonathan Deutsch; Mark Demario; Razelle Kurzrock; Jennifer J Wheler Journal: J Clin Oncol Date: 2012-04-23 Impact factor: 44.544
Authors: Peng Jiang; Shengqing Gu; Deng Pan; Jingxin Fu; Avinash Sahu; Xihao Hu; Ziyi Li; Nicole Traugh; Xia Bu; Bo Li; Jun Liu; Gordon J Freeman; Myles A Brown; Kai W Wucherpfennig; X Shirley Liu Journal: Nat Med Date: 2018-08-20 Impact factor: 53.440
Authors: Antonio Cigliano; Shanshan Zhang; Silvia Ribback; Sara Steinmann; Marcella Sini; Cindy E Ament; Kirsten Utpatel; Xinhua Song; Jingxiao Wang; Maria G Pilo; Fabian Berger; Haichuan Wang; Junyan Tao; Xiaolei Li; Giovanni M Pes; Serena Mancarella; Gianluigi Giannelli; Frank Dombrowski; Matthias Evert; Diego F Calvisi; Xin Chen; Katja Evert Journal: J Exp Clin Cancer Res Date: 2022-06-03
Authors: Xinjun Lu; Baogang Peng; Ge Chen; Mario G Pes; Silvia Ribback; Cindy Ament; Hongwei Xu; Rajesh Pal; Pedro M Rodrigues; Jesus M Banales; Matthias Evert; Diego F Calvisi; Xin Chen; Biao Fan; Jingxiao Wang Journal: Am J Pathol Date: 2021-06-12 Impact factor: 5.770
Authors: Ainhoa Lapitz; Ander Arbelaiz; Colm J O'Rourke; Jose L Lavin; Adelaida La Casta; Cesar Ibarra; Juan P Jimeno; Alvaro Santos-Laso; Laura Izquierdo-Sanchez; Marcin Krawczyk; Maria J Perugorria; Raul Jimenez-Aguero; Alberto Sanchez-Campos; Ioana Riaño; Esperanza Gónzalez; Frank Lammert; Marco Marzioni; Rocio I R Macias; Jose J G Marin; Tom H Karlsen; Luis Bujanda; Juan M Falcón-Pérez; Jesper B Andersen; Ana M Aransay; Pedro M Rodrigues; Jesus M Banales Journal: Cells Date: 2020-03-14 Impact factor: 6.600